When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ZGNX - Zogenix Has A Wide Margin Of Safety After A 60% Sell-Off
Zogenix Inc.
Zogenix just launched Fintepla, a product to treat Dravet syndrome.
GW Pharma already has a Fintepla competitor Epidiolex approved and growing big sales in Dravet syndrome and other indications that Fintepla will likely expand to.
Zogenix’s major sell-off makes its valuation look like the more attractive one as compared to GW Pharma despite both companies' promising long-term potential.